Showing 3651-3660 of 7608 results for "".
- Arcutis Moves Another Candidate Into Phase 3 Trialshttps://practicaldermatology.com/news/arcutis-moves-another-candidate-into-phase-3-trials/2460664/Roughly a week after announcing plans to initiate Phase 3 clinical trials for topical roflumilast cream (ARQ-151) in the treatment of atopic dermatitis (AD),
- LEO Pharma Data: Tralokinumab Benefits Adult ADhttps://practicaldermatology.com/news/leo-pharma/2460662/Results from a post-hoc subanalysis of the Phase 3 ECZTRA 3 trial demonstrate the potential for LEO Pharma’s tralokinumab as a treatment for adults with moderate-to-severe atopic dermatitis. Investigational tralokinumab has not y
- Verrica: Post-Hoc Analyses Show Benefits of VP-102 at Specific Siteshttps://practicaldermatology.com/news/verrica-post-hoc-analyses-show-benefits-of-vp-102-at-specific-sites/2460661/Positive data from post-hoc pooled analyses of the pivotal Phase 3 CAMP trials demonstrate the safety and efficacy of Verrica Pharmaceuticals’ lead product candidate VP-102 in molluscum contagiosum (molluscum) in specific body regions. The data were presented in poster format online for the
- RealSelf Acquires Tajmeeli.com to Serve Arabic-Speaking Medical Aesthetics Markethttps://practicaldermatology.com/news/realself-acquires-tajmeelicom-to-aerve-arabic-speaking-medical-aesthetics-market/2460660/RealSelf now owns Tajmeeli, the leading cosmetic procedure resource for Arabic speaking consumers. The acquisition adds one million Arabic-speaking monthly active users. "We're excited this acquisition will enable us to expand our reach and resources to over 100 countries
- Study: Acute Itching in AD Linked to Environmental Triggershttps://practicaldermatology.com/news/study-acute-itching-in-ad-linked-to-environmental-triggers/2460658/Allergens in the environment often are to blame for episodes of acute itch in eczema patients, and that this itching often doesn’t respond to antihistamines because the itch signals are being carried to the brain along a previously unrecognized pathway that current drugs don’t ta
- New Merz and Candela Collab Announcedhttps://practicaldermatology.com/news/new-merz-candela-collab-announced/2460655/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales representatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally inte
- Arcutis Starts Phase 3 Trials of Topical Roflumilast Cream for ADhttps://practicaldermatology.com/news/arcutis-starts-phase-3-trials-of-topical-roflumilast-cream-for-ad/2460654/Arcutis Biotherapeutics, Inc. is starting their pivotal Phase 3 clinical trials evaluating topical roflumilast cream (ARQ-151) as a potential treatment for atopic dermatitis (AD). Roflumilast cream is a once daily topical formulation of roflumilast, a highly potent and s
- DermTech Closes Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shareshttps://practicaldermatology.com/news/dermtech-closes-public-offering-of-common-stock-and-full-exercise-of-underwriters-option-to-purchase-additional-shares/2460651/DermTech, Inc. closed its previously announced underwritten public offering of 4,872,881 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase up to 635,593 additional shares, at a price to the public of $29.50 per share, the company
- Answered: Your Questions About Employee Management and COVID Risk Mitigationhttps://practicaldermatology.com/news/answered-your-questions-about-employee-management-and-covid-risk-mitigation/2460650/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there ar
- DermBiont Releases Positive Phase 2 Data for DBI-001 in Tinea pedis, Atopic dermatitishttps://practicaldermatology.com/news/dermbiont-releases-positive-phase-2-data-for-dbi-001-in-tinea-pedis-atopic-dermatitis/2460649/Data from two, separate phase 2 clinical trials of investigational DBI-001 for the treatment of tinea pedis and atopic dermatitis show benefit, according to drug developer DermBiont. In the phase 2b clinical study of DBI-001 in tinea p